SP2086
Drugall subjects were given SP2086 50mg only one time.
NCT Number: NCT02815774
The purpose of the study is to investigate the SP2086 pharmacokinetic in Renal Insufficiency Patients.
Looking for future studies?
Notify Me18 year–79 year
All sexes
Interventional
Phase 1
This trial adopt in a parallel, open, single dose study design. The subject was divided into one of five groups according to the degree of renal Insufficiency, which including normal, mild, moderate, severe, and end-stage. All subjects were given SP2086 50mg, and collected the blood samples before and after the medicine taken.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
all subjects were given SP2086 50mg only one time.
Time frame: up to 96 hours
Cmax (a measure of the body's exposure to SP2086) will be compared before and after administration of a single dose of SP2086
Time frame: up to 96 hours
Cmax (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of a single dose of SP2086
Time frame: up to 96 hours
AUC (a measure of the body's exposure to SP2086) will be compared before and after administration of a single dose of SP2086
Time frame: up to 96 hours
AUC (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of a single dose of SP2086
Time frame: up to 96 hours
Jiangsu HengRui Medicine Co., Ltd.
Industry
A Parallel, Open Phase Ih Study to Access the Pharmacokinetic of SP2086 in Renal Insufficiency Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05936138
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Miami, Florida, United States
View Trial DetailsNCT06890208
Anxiety Disorders, Arrhythmias, Cardiac
Hamburg, Germany
View Trial DetailsNCT04876963
Arrhythmias, Cardiac, Cardiovascular Diseases
Copenhagen, Denmark
View Trial DetailsNCT07165015
Chronic Disease, Disease Attributes
Orlando, Florida, United States
View Trial Details